<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T19:44:30Z</responseDate><request verb="GetRecord" identifier="oai:digital.lib.washington.edu:1773/43906" metadataPrefix="dim">https://digital.lib.washington.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:digital.lib.washington.edu:1773/43906</identifier><datestamp>2026-02-16T02:03:35Z</datestamp><setSpec>com_1773_4888</setSpec><setSpec>col_1773_19679</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Babigumira, Joseph B</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Steuten, Lotte MG</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" authority="3529cbd3-b68a-4246-9943-f039eec8e47a" confidence="300">Puronen, Camille Eileen</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2019-08-14T22:25:59Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2019-08-14T22:25:59Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2019-08-14</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="submitted">2019</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">Puronen_washington_0250O_20054.pdf</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/1773/43906</dim:field>
   <dim:field mdschema="dc" element="description">Thesis (Master's)--University of Washington, 2019</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract">Background: Rituximab is a monoclonal antibody that confers a survival benefit in adults with aggressive B cell Non-Hodgkin Lymphoma (B-NHL), and has been shown to be cost-effective in in high-income settings. Rituximab is not widely available in Uganda and other low-income countries due to cost.  This is an evaluation of the potential cost-utility of the addition of rituximab (R-CHOP) to standard first-line chemotherapy (CHOP) for adults with aggressive B-NHL.  Methods: A Markov model was developed to evaluate R-CHOP vs CHOP in adults with aggressive B-NHL treated at the Uganda Cancer Institute (UCI) over a lifetime horizon, from the perspective of the Uganda Ministry of Health. Main outcomes were disability-adjusted life-years (DALYs) averted and the incremental cost effectiveness ratio (ICER). A 3% discount rate was applied. Sensitivity analyses were performed to evaluate uncertainty. Results: The addition of rituximab to CHOP increased life-years (LYs) by 0.32 years (1.96 years with R-CHOP vs 1.62 years with CHOP) and decreased DALYs by 0.05 (0.32 with R-CHOP vs 0.26 with CHOP). The incremental cost of adding rituximab to CHOP was $3,153 per patient. The ICER comparing R-CHOP vs. CHOP was $9,313 per LY gained and $60,719 per DALY averted. Conclusions: Compared to a cost-effectiveness threshold of 3 times GDP per capita ($1,812 for Uganda in 2019 USD), rituximab is not cost-effective in this setting. As rituximab has been shown to improve to outcomes in adults with aggressive B-NHL, the Ugandan Ministry of Health may wish to further evaluate pricing options.</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso">en_US</dim:field>
   <dim:field mdschema="dc" element="rights">none</dim:field>
   <dim:field mdschema="dc" element="subject">Cost-Effectiveness</dim:field>
   <dim:field mdschema="dc" element="subject">Cost-Utility</dim:field>
   <dim:field mdschema="dc" element="subject">Health Economics</dim:field>
   <dim:field mdschema="dc" element="subject">Non-Hodgkin Lymphoma</dim:field>
   <dim:field mdschema="dc" element="subject">Rituximab</dim:field>
   <dim:field mdschema="dc" element="subject">Uganda</dim:field>
   <dim:field mdschema="dc" element="subject">Public health</dim:field>
   <dim:field mdschema="dc" element="subject">Economics</dim:field>
   <dim:field mdschema="dc" element="subject">Medicine</dim:field>
   <dim:field mdschema="dc" element="subject" qualifier="other">Global Health</dim:field>
   <dim:field mdschema="dc" element="title">Analysis of the Potential Cost Utility of the Addition of Rituximab to Standard Chemotherapy in Adults with Aggressive B Cell Non-Hodgkin Lymphoma in Uganda</dim:field>
   <dim:field mdschema="dc" element="type">Thesis</dim:field>
   <dim:field mdschema="dc" element="embargo" qualifier="terms">Open Access</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>